# PolQ as a novel therapeutic target in AML

> **NIH NIH R01** · TEMPLE UNIV OF THE COMMONWEALTH · 2022 · $535,835

## Abstract

Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with overall 
poor prognosis. More specific therapies have been developed against FLT3(ITD/TKD)-positive AML 
(FLT3 tyrosine kinase inhibitors, TKi). Still, complete remissions are rare, and after initial 
response the leukemia invariably progresses within a few months.
AML cells accumulate lethal DNA double-strand breaks (DSBs), but DSB repair pathways 
maintain their survival. BRCA1/2-mediated homologous recombination (HR) usually plays a major role 
in DSB repair. However, we reported that leukemias expressing AML1-ETO and PML-RAR, 15- 35% of 
karyotypic normal AMLs, and TKi – treated FLT3(ITD/TKD)-positive AMLs (39% of karyotypic 
normal AMLs) are HR-deficient. Proliferation of HR-deficient solid tumor cells depends on DNA 
polymerase theta (Polθ) encoded by POLQ gene, which promotes a backup DSB repair called 
microhomology-mediated end-joining (MMEJ). According to cBioPortal database AMLs express the 
highest levels of POLQ mRNA among all tumors. Western blot analysis detected high levels of Polθ in 
AML cells when compared to normal counterparts. Altogether, these findings 
supported by preliminary data suggest that survival of AML cells (especially 
HR-deficient), which are under constant genotoxic stress, depends on Polθ. Therefore, 
Polθ may be a novel and promising drug target in AML.
Our preliminary data suggest that AML-inducing mutations [FLT3(ITD/TKD) +/- TET2mut, 
DNMT3Amut, MLL-AF9, AML1-ETO] can modulate the sensitivity of AML cells to the inhibition of Polθ. 
Therefore, in Aim #1 we will inhibit Polθ (shRNA, mutants and Polq-/- cells) and introduce 
AML-inducing mutations (retroviral infection, CRISPR/Cas9) to pinpoint mutations, 
which predispose leukemia cells to be sensitive to Polθ inhibition +/- standard cytotoxic drugs.
Using high throughput screening followed by biochemical testing and in vitro cellular sensitivity 
assays, we identified Polθ inhibitors (Polθi) that specifically kill HR-deficient primary AML 
cells. In Aim #2 we will further develop Polθi towards novel drug-like entities as targeted 
therapeutics for AMLs.
In Aim #3 we will employ murine AML-like models, primary AML cells and xenografts to test 
therapeutic potential of inhibition of Polθ combined with (1) other DNA repair inhibitors (RAD52i, 
PARPi) against HR-deficient AMLs, and (2) standard cytotoxic drugs against HR-proficient AMLs.
We anticipate that Polθi developed in these studies will be effective against a wide-range of AMLs 
and ultimately will be advanced to clinical trials.

## Key facts

- **NIH application ID:** 10322361
- **Project number:** 5R01CA244179-03
- **Recipient organization:** TEMPLE UNIV OF THE COMMONWEALTH
- **Principal Investigator:** Richard T Pomerantz
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $535,835
- **Award type:** 5
- **Project period:** 2020-01-17 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10322361

## Citation

> US National Institutes of Health, RePORTER application 10322361, PolQ as a novel therapeutic target in AML (5R01CA244179-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10322361. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*